biomedicines

IMPACT FACTOR 3.9

Indexed in: PubMed

CITESCORE 5.2

an Open Access Journal by MDPI

Advanced Research in Heme Oxygenase

Guest Editors:

Dr. Terry D Hinds, Jr.
Pharmacology and Nutritional Sciences, College of Medicine, University of Kentucky, Lexington, KY 40508, USA

Dr. David E. Stec
Center for Excellence in Cardiovascular-Renal Research, Department of Physiology & Biophysics, University of Mississippi Medical Center, 2500 North State St., Jackson, MS 392161, USA

Deadline for manuscript submissions:
closed (31 July 2024)

Message from the Guest Editors

Heme oxygenase (Hmox) has been studied for many decades and is known to be the enzyme responsible for the breakdown of heme, which occurs in all cells in the body. It generates carbon monoxide (CO), biliverdin, which is reduced by biliverdin reductase to bilirubin, and free iron. Heme oxygenase and its related enzymes and metabolites play an important role in several physiological and pathological processes, including cancer, diabetes, heart and kidney disease, hypertension, inflammation, obesity, and neurological diseases. This Special Issue solicits exciting new advances in heme oxygenase biology, its related enzymes for synthesis or catabolism, and its metabolites. The latest in preclinical and clinical trials and timely reviews highlighting the importance of heme oxygenase and its related metabolites will be incorporated into the Special Issue. The goal is to expand upon what has been known about Hmox and extend this into new advancements, whether that might be detection instruments, new ligand agonists or antagonists, and possible new discoveries not yet known.

biomedicines

IMPACT FACTOR 3.9 | Indexed in: PubMed | CITESCORE 5.2

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI